Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older.
- You have been diagnosed with a specific type of early-stage breast cancer (stage T1 or T2 invasive ductal or lobular), regardless of hormone receptor or HER2 status.
- Your lymph nodes under the arm feel normal to the touch, and an ultrasound scan shows no more than two suspicious lymph nodes in that area.
- A biopsy (tissue sample) has confirmed that cancer has spread to at least one lymph node under the arm.
- You are generally able to carry out daily activities and care for yourself — your doctor will assess this using a standard performance scale (confirm with trial site).
- You are willing and able to read, understand, and sign the consent form for the trial.
Who may not be able to join:
- You have previously had surgery on the lymph nodes under the arm on the same side as the breast cancer, including a sentinel lymph node biopsy.
- Your cancer has already spread to other parts of the body (distant metastases).
- You have previously had radiotherapy treatment to the lymph nodes under the arm.
- You have already received chemotherapy, hormone therapy, or other treatments before surgery (neoadjuvant therapy).
- If a blue dye injection is planned as part of the procedure, you cannot join if you have a known allergy or sensitivity to certain blue dyes or similar substances used in the process (confirm with trial site).
- You are unable to give your own informed consent to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean-François Boileau, MD,MSc,FRCSC, Jewish General Hospital
Phone: 514-340-8222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction in recommended completion node dissection rate (CND) with the use of Targeted Axillary Dissection (TAD) vs. Sentinel Node Biopsy (SNB) alone.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.